Contraindications to Thrombolytic Therapy in STEMI

Absolute Contraindications

Neurological

Prior intracranial hemorrhage at any time precludes fibrinolysis (ACC/AHA Class III, Harm) 1
Ischemic stroke within the preceding 3 months is an absolute contraindication (ACC/AHA Class III, Harm) 1
Known structural cerebral vascular lesions (e.g., arteriovenous malformation, aneurysm) forbid thrombolytic use (ACC/AHA Class III, Harm) 1
Malignant intracranial neoplasm (primary or metastatic) is an absolute contraindication (ACC/AHA Class III, Harm) 1
Intracranial or intraspinal surgery performed within the past 2 months excludes thrombolysis (ACC/AHA Class III, Harm) 1
Significant closed‑head or facial trauma within 3 months is an absolute contraindication (ACC/AHA Class III, Harm) 1

Bleeding‑Related

Active internal bleeding (excluding menstrual bleeding) is an absolute contraindication (ACC/AHA Class III, Harm) 1
Known bleeding diathesis such as thrombocytopenia or coagulopathy precludes fibrinolytic therapy (ACC/AHA Class III, Harm) 1

Cardiovascular

Suspected aortic dissection is an absolute contraindication (ACC/AHA Class III, Harm) 1
Severe uncontrolled hypertension unresponsive to emergency therapy (e.g., SBP > 180 mm Hg or DBP > 110 mm Hg) is an absolute contraindication (ACC/AHA Class III, Harm) 1

ECG‑Based

Isolated ST‑segment depression on the ECG (without posterior ST elevation or aVR elevation) is a Class III (Harm) contraindication because fibrinolysis offers no benefit and may cause harm in NSTEMI (ACC/AHA; also cited by AAFP) [2][1]

Agent‑Specific

Prior streptokinase administration within the previous 6 months is an absolute contraindication to repeat streptokinase due to risk of severe allergic reaction (ACC/AHA) 1

Relative Contraindications

Chronic severe hypertension that is poorly controlled (ACC/AHA) 1
Presentation with severe hypertension (SBP > 180 mm Hg or DBP > 110 mm Hg) (ACC/AHA) 1
Prior ischemic stroke occurring more than 3 months ago (ACC/AHA) 1
Dementia or other intracranial pathology not meeting absolute criteria (ACC/AHA) 1
Prolonged (>10 min) traumatic CPR (ACC/AHA) 1
Major non‑cardiac surgery within the past 3 weeks (ACC/AHA) 1
Recent internal bleeding (within 2–4 weeks) (ACC/AHA) 1
Non‑compressible vascular puncture sites (ACC/AHA) 1
Pregnancy (ACC/AHA) 1
Active peptic ulcer disease (ACC/AHA) 1
Current oral anticoagulant therapy (ACC/AHA) 1

Clinical Decision‑Making Algorithm

Confirm STEMI by ≥2 contiguous leads with ST‑segment elevation or new left bundle‑branch block, and symptom onset ≤12 h (ACC/AHA; also cited by AAFP) [2][1]3
If isolated ST‑segment depression is present (without posterior MI or aVR elevation), withhold thrombolysis (ACC/AHA) 1
Presence of any absolute contraindication eliminates fibrinolysis as an option (ACC/AHA) 1
For relative contraindications, balance bleeding risk against ischemic benefit considering infarct size, hemodynamic status, and symptom duration (ACC/AHA) 1
Primary PCI is preferred when achievable within 120 minutes of first medical contact; otherwise, thrombolysis may be used if no contraindications exist (ACC/AHA; also ESC) [3][4]

Common Clinical Pitfalls

Age – Advanced age (>75 years) is not a contraindication; elderly patients derive the greatest absolute mortality benefit, and only ≈9 % have absolute contraindications (ACC/AHA) 5
Relative contraindications should not automatically preclude thrombolysis in patients with large infarcts, hemodynamic instability, or when PCI is unavailable, because mortality benefit usually outweighs bleeding risk (ACC/AHA) 1
Cardiogenic shock – Not a contraindication; patients with STEMI and shock who cannot receive PCI or CABG should receive fibrinolysis (ESC; ACC/AHA) [4][1]
Recent surgery – Intracranial/intraspinal surgery within 2 months is an absolute contraindication, whereas non‑cranial surgery within 3 weeks is only relative (ACC/AHA) 1
Late presentation – Symptom onset >12 h is not an absolute contraindication if ongoing ischemia, large myocardium at risk, or hemodynamic instability persists and PCI is unavailable (ACC/AHA) 1

Thrombolysis in STEMI

Primary Recommendation

The European Society of Cardiology recommends reperfusion therapy in all patients with symptoms of ischemia ≤12 hours duration and persistent ST-segment elevation, regardless of Q wave presence, with Class I, Level A evidence 6, 7
The American College of Cardiology/American Heart Association recommends fibrinolytic therapy for STEMI patients with symptom onset <12 hours when anticipated delay to primary PCI exceeds 120 minutes from first medical contact, with Class I, Level A evidence 8

Clinical Algorithm

If primary PCI is available within 120 minutes of first medical contact, transfer for primary PCI is recommended with Class I, Level A evidence 6, 8
If primary PCI is not available within 120 minutes, administer fibrinolytic therapy immediately, preferably pre-hospital, with Class I, Level A evidence 6, 7, 8
Use fibrin-specific agents, such as tenecteplase, alteplase, or reteplase, for fibrinolytic therapy 6, 8
Administer aspirin and clopidogrel, and use enoxaparin or UFH for anticoagulation 6, 7

Contraindications

The only ECG finding that contraindicates thrombolysis is ST depression (except true posterior MI or ST elevation in aVR), with Class III: Harm, Level B evidence 8, 9, 10, 11
Other absolute contraindications include prior intracranial hemorrhage, known structural cerebral vascular lesions, ischemic stroke within 3 months, active bleeding, or severe uncontrolled hypertension 9, 12

Asymptomatic Late Presenters

Do not perform routine PCI of an occluded infarct-related artery >48 hours after STEMI onset in asymptomatic patients with completed infarction, with Class III, Level A evidence 6, 8
The DECOPI trial showed no benefit in patients with Q waves presenting 2-15 days after symptom onset who were asymptomatic 8, 13

Contraindications to Thrombolytic Therapy in Acute Myocardial Infarction

Absolute Contraindications (ACC/AHA & ESC)

Prior intracranial hemorrhage at any time permanently excludes fibrinolysis in STEMI patients. 14
Ischemic stroke within the preceding 3 months (some guidelines extend to 6 months) is an absolute exclusion. [14][15]
Known structural cerebral vascular lesions (e.g., arteriovenous malformation or aneurysm) preclude thrombolytic use. 14
Malignant intracranial neoplasm (primary or metastatic) is an absolute contraindication. 14
Significant closed‑head or facial trauma occurring within the past 3 months bars fibrinolysis. [14][15]
Active internal bleeding (excluding menstrual bleeding) makes thrombolysis unsafe. [14][15]
Documented bleeding diathesis such as thrombocytopenia or coagulopathy contraindicates fibrinolysis. [14][15]
Suspected aortic dissection is an absolute exclusion for thrombolytic therapy. [14][15]
Severe uncontrolled hypertension (SBP > 180 mm Hg or DBP > 110 mm Hg) that does not respond to emergency treatment contraindicates thrombolysis. [14][15]
Prior exposure to streptokinase or anistreplase within 6 months to 10 years (due to antibody formation) is an absolute contraindication. 15

Relative Contraindications (ACC/AHA & ESC)

Transient ischemic attack within the preceding 6 months warrants careful risk‑benefit assessment before thrombolysis. [14][15]
Prior ischemic stroke occurring > 3 months ago, dementia, or other intracranial pathology that does not meet absolute criteria should be evaluated individually. 14
Chronic severe hypertension that is poorly controlled, as well as severe hypertension on presentation that is responsive to treatment, are relative contraindications. [14][15]
Prolonged cardiopulmonary resuscitation (>10 minutes) or traumatic CPR requires individualized decision‑making. [14][15]
Major non‑cranial surgery performed within the preceding 3 weeks is a relative contraindication. [14][15]
Recent internal bleeding within 2–4 weeks increases bleeding risk and should be weighed against ischemic benefit. [14][15]
Gastro‑intestinal bleeding within the last month is generally an absolute contraindication in stable STEMI but may become relative in massive pulmonary embolism with shock. [16][17]
Non‑compressible vascular puncture sites are relative contraindications. [14][15]
Pregnancy or the first week postpartum require individualized assessment. [14][15]
Active peptic ulcer disease, current oral anticoagulant therapy (elevated INR), advanced liver disease, and infective endocarditis are each relative contraindications that demand a balanced decision. [14][15][16][17]

Clinical Decision Algorithm (ESC)

Step 1 – STEMI Confirmation: Diagnosis requires ≥2 contiguous leads with ST‑segment elevation or a new left bundle‑branch block, with symptom onset ≤12 hours. 18
Step 2 – Absolute Contraindication Screen: Presence of any absolute contraindication eliminates fibrinolysis as an option. 14
Step 3 – PCI Availability: If primary PCI can be performed within 120 minutes of first medical contact, transfer for PCI is preferred over thrombolysis. 18
Step 4 – Thrombolysis Initiation: When PCI is unavailable and no absolute contraindications exist, administer a fibrin‑specific thrombolytic agent immediately, ideally in the pre‑hospital setting. 18
Step 5 – Relative Contraindication Assessment: Weigh bleeding risk against ischemic benefit considering infarct size, hemodynamic status, and symptom duration. 14
Step 6 – Agent Selection: Use fibrin‑specific agents (tenecteplase, alteplase, or reteplase) together with aspirin, clopidogrel, and either enoxaparin or unfractionated heparin. [18][15]

Critical Clinical Pitfalls (ACC/AHA & ESC)

Advanced age (>75 years) is not a contraindication; elderly patients derive the greatest absolute mortality benefit, and only ≈9 % have true absolute contraindications. 19
Cardiogenic shock does not preclude fibrinolysis when immediate PCI is unavailable. 18
Relative contraindications should not automatically exclude treatment; in large infarcts, hemodynamic instability, or when PCI is not feasible, mortality benefit usually outweighs bleeding risk. 14
Symptom onset >12 hours is not an absolute barrier; ongoing ischemia, large myocardium at risk, or instability may justify thrombolysis if PCI cannot be delivered promptly. 18

Evidence Quality & Outcomes (ACC/AHA & ESC)

The ACC/AHA and ESC guidelines provide the most comprehensive and consistent lists of thrombolytic contraindications. [14][15]18
In the TETAMI trial, the incidence of absolute contraindications was only 1.4 %, indicating substantial under‑use of thrombolysis due to perceived rather than actual barriers. 19
Major bleeding occurs in approximately 13 % of patients receiving thrombolysis, with intracranial hemorrhage in about 1.8 % of cases. [16][17]

Management of STEMI When Thrombolysis Is Contraindicated

Absolute Contraindications to Thrombolysis

Ischemic stroke within the preceding 3 months precludes the use of fibrinolytic therapy in patients with STEMI. 20
Active internal bleeding (excluding menstrual bleeding) is an absolute exclusion for thrombolysis. 20
Known bleeding diathesis such as thrombocytopenia or coagulopathy contraindicates fibrinolytic administration. 20
Gastro‑intestinal bleeding within the last month makes thrombolysis inappropriate. 20
Suspected aortic dissection is a definitive contraindication to any thrombolytic agent. 20

Relative Contraindications to Thrombolysis

Major non‑cardiac surgery performed within the past 3 weeks requires careful risk‑benefit assessment before considering fibrinolysis. 20

Primary PCI as the Preferred Alternative

Immediate transfer for primary percutaneous coronary intervention (PCI) is the recommended reperfusion strategy for patients with absolute contraindications to thrombolysis, as it is the only method that reliably restores coronary flow and reduces mortality. 20
Direct transport to the catheterisation laboratory, bypassing the emergency department and including inter‑hospital transfer when necessary, shortens treatment delays. 21
Primary PCI is feasible and safe in the overwhelming majority of patients who cannot receive thrombolysis. 20

Pharmacologic Adjuncts for Primary PCI

Aspirin combined with a P2Y12 inhibitor (prasugrel or ticagrelor, not clopidogrel) should be administered before PCI. 21
Unfractionated heparin is the first‑line anticoagulant during primary PCI in this setting. 21

Timing Considerations for Transfer

If primary PCI can be performed within 120 minutes of first medical contact, transfer is strongly favoured over thrombolysis even when no contraindications exist. 21

Decision‑Making Algorithm (Key Steps)

Confirm STEMI by demonstrating ≥2 contiguous leads with ST‑segment elevation or a new left‑bundle‑branch block and symptom onset ≤12 hours. 21
Screen for absolute contraindications; their presence eliminates fibrinolysis as an option.
Assess PCI availability: when a PCI‑capable centre can be reached within 120 minutes, prioritize transfer for primary PCI. 21
When PCI is unavailable and no absolute contraindications exist, initiate a fibrin‑specific thrombolytic (tenecteplase, alteplase, or reteplase) within 10 minutes, preferably pre‑hospital. 21
Provide adjunctive therapy: aspirin, clopidogrel (when fibrinolysis is used), and either enoxaparin or unfractionated heparin. 21
All patients who receive thrombolysis must be transferred to a PCI‑capable centre for coronary angiography between 2 and 24 hours after successful fibrinolysis, or immediately if fibrinolysis fails. 21

Surgical/Catheter Embolectomy for High‑Risk Pulmonary Embolism

Surgical pulmonary embolectomy is recommended for patients with massive pulmonary embolism when thrombolysis is absolutely contraindicated or has failed. 22
Catheter‑based embolectomy or fragmentation may be considered when surgical embolectomy is not immediately available. 22